{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T13:41:52Z","timestamp":1648820512911},"reference-count":42,"publisher":"Czech Society of Ophthalmology of the CzMA","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CSO"],"published-print":{"date-parts":[[2019,7,8]]},"abstract":"<jats:p>Purpose: Evaluate the effectiveness of treatment of patients with optic pathway glioma.\n\nMaterials and Methods: Comparison of literature research on neurofibromatosis and optic pathway glioma with a cohort of pediatric patients treated at the Children\u2018s Ophthalmology Clinic of the University Hospital in Brno from January 2013 until June 2018.\n\nDiscussion: The main challenge of this and other retrospective studies is variable intervals between ophthalmologic examinations. In some pediatric patients it is also difficult to objectively assess visual functions. The main risk factors are age at the time of treatment and tumor localization. Tumor progression itself does not always correlate with worse visual acuity outcomes, and it remains to be evaluated whether some patients would be better off without treatment. As of now, there are no clinical biomarkers able to predict impending visual acuity loss.\n\nConclusion: The cohort outcome agrees with literature. Chemotherapy remains a treatment of choice and its most likely outcome is visual acuity stabilization. In order to properly evaluate the treatment\u2019s effectiveness, better collaboration between medical specialists and regular standardized ophthalmology examinations are required.<\/jats:p>","DOI":"10.31348\/2019\/4\/4","type":"journal-article","created":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T12:38:23Z","timestamp":1599482303000},"page":"200-208","source":"Crossref","is-referenced-by-count":1,"title":["Neurofibromatosis Type 1 and Optic Pathway Glioma"],"prefix":"10.31348","volume":"75","author":[{"given":"Aneta","family":"Siw\u00e1","sequence":"first","affiliation":[{"name":"D\u011btsk\u00e1 o\u010dn\u00ed klinika LF MU a FN Brno"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RUdolf","family":"Autrata","sequence":"additional","affiliation":[{"name":"D\u011btsk\u00e1 o\u010dn\u00ed klinika LF MU a FN Brno"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kl\u00e1ra","family":"Vejm\u011blkov\u00e1","sequence":"additional","affiliation":[{"name":"Children\u2019s Ophthalmology Clinic, Faculty of Medicine, Masaryk University and University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zden\u011bk","family":"Pavelka","sequence":"additional","affiliation":[{"name":"Children\u2019s Ophthalmology Clinic, Faculty of Medicine, Masaryk University and University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Zitterbart","sequence":"additional","affiliation":[{"name":"Children\u2019s Ophthalmology Clinic, Faculty of Medicine, Masaryk University and University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16213","published-online":{"date-parts":[[2020,1,6]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Aihara, Y., Chiba, K., Eguchi, S. et al.: Pediatric Optic Pathway\/Hypothalamic Glioma. Neurol Med Chir, 58(1); 2018: 1\u20139.","DOI":"10.2176\/nmc.ra.2017-0081"},{"key":"ref1","unstructured":"Autrata, R.: Choroby v\u00ed\u010dek a\u00a0orbity. In Autrata, R. (Ed), D\u011btsk\u00e1 oftalmologie I. \u010d\u00e1st. Sborn\u00edk prac\u00ed l\u00e9ka\u0159sk\u00e9 fakulty Masarykovy univerzity \u010d. 122. Masarykova univerzita, Brno, 2008, s. 16\u201317."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Awdeh, RM., Keihna, EN., Drewry, RD. et al.: Visual outcomes in pediatric optic pathway glioma after conformal radiation therapy. Int J Radiat Oncol Biol Phys, 84(1); 2012: 46\u201351.","DOI":"10.1016\/j.ijrobp.2011.10.067"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Bakker, AC., La Rosa, S., Sherman, LS. et al.: Neurofibromatosis as a\u00a0gateway to better treatment for a\u00a0variety of malignancies. Prog Neurobiol, 2017(152): 149\u2013165.","DOI":"10.1016\/j.pneurobio.2016.01.004"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Balcer, LJ., Liu, GT., Heller, G. et al.: Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging. Am J Ophthalmol, 131(4); 2001: 442\u2013445.","DOI":"10.1016\/S0002-9394(00)00852-7"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Cameron, F., Parsa, R.: Neurogenic tumors. In Pediatric Ophthalmology and Strabismus Fourth Edition. Eds Hoyt, C.S., Taylor, D. Edinburgh: Elsevier Ltd., 2012, s. 206\u2013215.","DOI":"10.1016\/b978-0-7020-4691-9.00023-6"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Campen, CJ., Gutmann, DH.: Optic Pathway Gliomas in Neurofibromatosis Type 1. J Child Neurol, 33(1); 2017: 73\u201381.","DOI":"10.1177\/0883073817739509"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Ceballos-Quintal, JM., Pinto-Escalante, D.,\u00a0Castillo-Zapata, I. et al.: A\u00a0new case of Klippel-Trenaunay-Weber (KTW) syndrome: Evidence of autosomal dominant inheritance. Am J Med Genet, 63(3); 1996: 426\u2013427.","DOI":"10.1002\/(sici)1096-8628(19960614)63:3<426::aid-ajmg2>3.0.co;2-p"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Dalla Via, P., Opocher E., Pinello, ML. et al.: Visual outcome of a\u00a0cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a\u00a0pediatric neuro-oncology program. Neuro Oncol, 9(4); 2007: 430\u2013437.","DOI":"10.1215\/15228517-2007-031"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"de Blank, PMK., Fisher, MJ., Liu, GT. et al.: Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision. J Neuroophthalmol, 37(Suppl); 2017: 23\u201332.","DOI":"10.1097\/WNO.0000000000000550"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Dodgshun, AJ., Elder, JE., Hansford, JR. et al.: Long\u2010term visual outcome after chemotherapy for optic pathway glioma in children: Site and age are strongly predictive. Cancer, 121(23); 2015: 4190\u20134196.","DOI":"10.1002\/cncr.29649"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Driever, PH., von Hornstein, S., Pietsch, T. et al.: Natural history and management of low-grade glioma in NF-1 children. J Neurooncol, 100(2); 2010: 199\u2013207.","DOI":"10.1007\/s11060-010-0159-z"},{"key":"ref12","unstructured":"Erdo\u011fan-Bakar, E., Cinbis, M., Ozy\u00fcrek, H. et al.: Cognitive functions in neurofibromatosis type 1 patients and unaffected siblings. Turk J Pediatr, 51(6); 2009: 565\u201371."},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Evans, DGR., Baser, ME.,\u00a0McGaughran, J. et al: Malignant peripheral nerve sheath tumors in neurofibromatosis. J Med Genet, 39(5); 2002: 311\u2013314.","DOI":"10.1136\/jmg.39.5.311"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Ferner, RE., Huson, SM., Thomas, N. et al.: Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet, 44(2); 2007: 81\u201388.","DOI":"10.1136\/jmg.2006.045906"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Fisher, MJ., Avery, RA., Allen, JC. et al.: Functional outcome measures for NF1-associated optic pathway glioma clinical trials. Neurology, 81(21 Suppl 1); 2013: 15\u201324.","DOI":"10.1212\/01.wnl.0000435745.95155.b8"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Fisher, MJ., Loguidice, M., Gutmann, DH. et al.: Visual outcomes in children with neurofibromatosis type 1\u2013associated optic pathway glioma following chemotherapy: a\u00a0multicenter retrospective analysis. Neuro Oncol, 14(6); 2012: 790\u2013797.","DOI":"10.1093\/neuonc\/nos076"},{"key":"ref17","unstructured":"Friedrich, RE., Nuding, MA.: Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a\u00a0Brief Review of the Literature. Anticancer Res, 36(8); 2016: 4095\u20134121."},{"key":"ref18","unstructured":"Gerinec, A.: Fakomat\u00f3zy. In Gerinec, A. (Ed), Detsk\u00e1 oftalmol\u00f3gia. Martin, Osveta, 2005, s. 517\u2013520."},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Gnekow, AK., Falkenstein, F., von Horstein, S. et al.: Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. J Neurooncol, 14(10); 2012: 1265\u20131284.","DOI":"10.1093\/neuonc\/nos202"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Grigg, J., Jamieson, R.: Phakomatoses. In Pediatric Ophthalmology and Strabismus Fourth Edition. Eds Hoyt, C.S., Taylor, D. Edinburgh: Elsevier Ltd., 2012, s. 675\u2013689.","DOI":"10.1016\/b978-0-7020-4691-9.00065-0"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Happle, R.: Klippel-Trenaunay syndrome: is it a\u00a0paradominant trait? Br J Dermatol, 128; 1993: 465.","DOI":"10.1111\/j.1365-2133.1993.tb00214.x"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Hudson, S., Beck, L.: Ophthalmic manifestations of neurofibromatosis. Br J Dermatol, 71(3); 1987: 235\u2013238.","DOI":"10.1136\/bjo.71.3.235"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Iannaccone, A., McCluney, RA.,\u00a0Brewer, VR. et al.: Visual evoked potentials in children with neurofibromatosis type 1. Doc Ophthalmol 105; 2002: 63\u201381.\u00a0","DOI":"10.1023\/A:1015719803719"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Kalin-Hajdu, E., D\u00e9carie, JC., Marzouki, M. et al.: Visual acuity of children treated with chemotherapy for optic pathway gliomas. Pediatr Blood Cancer, 61(2); 2013: 223\u2013227.","DOI":"10.1002\/pbc.24726"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Kissil, J., Blakeley, J., Ferner, R. et al.: What\u2019s\u00a0New in Neurofibromatosis? Proceedings from The 2009 NF Conference: New Frontiers. Am J Med Genet A, 152 A(2); 2010: 269\u2013283.","DOI":"10.1002\/ajmg.a.33189"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Korf, BR.: Clinical features and pathobiology of neurofibromatosis. J Child Neurol, 17(8); 2002: 573\u2013577.","DOI":"10.1177\/088307380201700806"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Moreno, L., Bautista F., Ashley S. et al.: Does chemotherapy affect the visual outcome in children with optic pathway glioma? A\u00a0systematic review of the evidence. Eur J Cancer, 46(12); 2010: 2253\u20132259.","DOI":"10.1016\/j.ejca.2010.03.028"},{"key":"ref28","unstructured":"Otradovec, J.: Lo\u017eiskov\u00e9 p\u0159\u00edznaky nitrolebn\u00edch n\u00e1dor\u016f. In Otradovec, J. (Ed), Klinick\u00e1 neurooftalmologie. Praha, Grada, 2003, s. 364\u2013367."},{"key":"ref29","unstructured":"Otradovec, J.: Fakomat\u00f3zy. In Otradovec, J. (Ed), Klinick\u00e1 neurooftalmologie. Praha, Grada, 2003, s. 396\u2013403."},{"key":"ref30","unstructured":"Otradovec, J.: Choroby zrakov\u00e9ho nervu. In Otradovec, J. (Ed), Klinick\u00e1 neurooftalmologie. Praha, Grada, 2003, s. 193\u2013196."},{"key":"ref31","unstructured":"Petr\u00e1k, B., Plevov\u00e1, P., Novotn\u00fd, J. et al.: Neurofibromatosis von Recklinghausen. Klin Onkol, 22(Suppl); 2009: 38\u201344."},{"key":"ref32","unstructured":"Petr\u00e1k, B., Bendov\u00e1, \u0160., Lis\u00fd, J. et al.: Neurofibromatosis von Recklinghausen typ 1 (NF1) \u2013 klinick\u00fd obraz a\u00a0molekul\u00e1rn\u011b-genetick\u00e1 diagnostika. Cesk Patol, 51(1); 2015: 34\u201340."},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Rakotonjanahary, J., De Carli, E., Delion, M. et al.: Mortality in Children with Optic Pathway Glioma Treated with Up-Front BB-SFOP Chemotherapy. PLoS ONE [online], 10(6); 22. \u010dervna 2015. [cit. 15. prosince 2018]. Dostupn\u00e9 na WWW: < https:\/\/doi.org\/10.1371\/journal.pone.0127676 >.","DOI":"10.1371\/journal.pone.0127676"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Rasool, N., Odel, JG., Kazim, M.: Optic pathway glioma of childhood. Curr Opin Ophthalmol, 28(3); 2017: 289\u2013295.","DOI":"10.1097\/icu.0000000000000370"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Robert-Boire, V., Rosca, L., Samson, Y. et al.: Clinical Presentation and Outcome of Patients With Optic Pathway Glioma. Pediatr Neurol, 75; 2017: 55\u201360.","DOI":"10.1016\/j.pediatrneurol.2017.06.019"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Singhal, S., Birch, JM., Kerr, B. et al.: Neurofibromatosis type 1 and sporadic optic gliomas. Arch Dis Child, 87(1); 2002: 65\u201370.","DOI":"10.1136\/adc.87.1.65"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Taylor, T., Jaspan, T., Milano, G. et al.: Radiological classification of optic pathway gliomas: experience of a\u00a0modified functional classification system. Br J Radiol, 81(970); 2008: 761\u2013766.","DOI":"10.1259\/bjr\/65246351"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Torres Nupan, MM., Van Meerbeke, AV., L\u00f3pez Cabra, CA. et al.: Cognitive and Behavioral Disorders in Children with Neurofibromatosis Type 1. Front Pediatr [online]. Frontiers Media S.A, 5(227); 2017. [cit. 15. prosince 2018]. Dostupn\u00e9 na WWW:<https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2017.00227\/full>","DOI":"10.3389\/fped.2017.00227"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Vivarelli, R., Grosso, S.,\u00a0Calabrese, F. et al.: Epilepsy in neurofibromatosis 1. J Child Neurol, 18(5); 2003: 338\u201342.","DOI":"10.1177\/08830738030180050501"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Walker, DA., Liu, J.,\u00a0Kieran, M. et al.: A\u00a0multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method. Neuro Oncol, 15(4); 2013: 462\u2013468.","DOI":"10.1093\/neuonc\/nos330"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"National Institute of Neurological Disorders and Stroke: Neurofibromatosis Fact Sheet. National Institute of Neurological Disorders and Stroke [online]. Kv\u011bten 2011. National Institute of Health, 11-2126.; 6. \u010dervence 2018. [cit. 15. prosince 2018]. Dostupn\u00e9 na WWW: https:\/\/www.ninds.nih.gov\/Disorders\/Patient-Caregiver-Education\/Fact-Sheets\/Neurofibromatosis-Fact-Sheet","DOI":"10.32388\/550292"}],"container-title":["Czech and Slovak Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T12:38:37Z","timestamp":1599482317000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cs-ophthalmology.cz\/en\/journal\/articles\/126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,8]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,1,6]]}},"URL":"https:\/\/doi.org\/10.31348\/2019\/4\/4","relation":{},"ISSN":["1805-4447","1211-9059"],"issn-type":[{"value":"1805-4447","type":"electronic"},{"value":"1211-9059","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,8]]}}}